Welcome to







. , .pdf-, . . , . , , . e-mail. , , . , : (495) 730-63-51 e-mail: atm-press2012@yandex.ru



-




  

2019 / N 2

: pros and cons
.. , .. , ..

References

1. Baig SS, Strong M, Quarrell OWJ. The global prevalence of Huntingtons disease: a systematic review and discussion. Neurodenenerative Disease Management 2016 Aug;6(4):331-43.
2. Huntington G. On chorea. Medical and Surgical Reporter (Philadelphia) 1872;26:317-21.
3. Illarioshkin SN, Klyushnikov SA, Seliverstov YuA. Huntingtons disease. Monograph. Moscow: Atmosphera; 2018. 472 p. (In Russian).
4. Hayden MR. Huntingtons chorea. Berlin, Heidelberg, New York: Springer-Verlag; 1981. 192 p.
5. Folstein SE. Huntingtons disease: a disorder of families. Baltimore: Johns Hopkins University Press; 1989. 251 p.
6. van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntingtons disease. The Lancet. Neurology 2009 Aug;8(8):765-74.
7. Cowan CM, Raymond LA. Selective neuronal degeneration in Huntingtons disease. Current Topics in Developmental Biology 2006;75:25-71.
8. The Huntingtons Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons disease chromosomes. Cell 1993 Mar;72(6):971-83.
9. Paulson HL. Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. American Journal of Human Genetics 1999 Feb;64(2):339-45.
10. Harding RJ, Tong YF. Proteostasis in Huntingtons disease: disease mechanisms and therapeutic opportunities. Acta Pharmacologica Sinica 2018 May;39(5):754-69.
11. Hands S, Sajjad MU, Newton MJ, Wyttenbach A. In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. The Journal of Biological Chemistry 2011 Dec;286(52):44512-20.
12. Reddy PH, Shirendeb UP. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntingtons disease. Biochimica et Biophysica Acta 2012 Feb;1822(2):101-10.
13. Skotte NH, Andersen JV, Santos A, Aldana B, Willert CW, Nørremølle A, Waagepetersen HS, Nielsen ML. Integrative haracterization of the R6/2 mouse model of Huntingtons disease reveals dysfunctional astrocyte metabolism. Cell Reports 2018 May;23(7):2211-24.
14. Mestre TA, Sampaio C. Huntington disease: linking pathogenesis to the development of experimental therapeutic. Current Neurology and Neuroscience Reports 2017 Feb;17(2):18.
15. Illarioshkin SN, Klyushnikov SA, Vigont VA, Seliverstov YuA, Kaznacheyeva EV. Molecular pathogenesis in Huntingtons disease. Biochemistry (Moscow) 2018 Sep;83(9):1030-9.
16. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Annals of Neurology 1995 Sep;38(3):357-66.
17. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacology & Therapeutics 1999 Mar;81(3):163-221.
18. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 2004 Jan;1:101-10.
19. Illarioshkin SN, Klyushnikov SA, Brylev LV, Fedin PA, Markova ED, Ivanova-Smolenskaya IA. Preventive neuroprotection in neurodegenerative diseases: glutamate receptor antagonists administration (review of literature and own experience). The Neurological Journal 2006;11(5):47-54 (In Russian).
20. Budd SL, Tenneti L, Lishnak T, Lipton SA. Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons. Proceedings of the National Academy of Sciences of the USA 2000 May;97(11):6161-6.
21. McGeer EG, McGeer PL. Duplication of biochemical changes of Huntingtons chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976 Oct;263(5577):517-9.
22. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntingtons disease. The Journal of Neuroscience 1991 Jun;11(6):1649-59.
23. Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, Raymond LA. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. Journal of Neurochemistry 1999 May;72(5):1890-8.
24. Zeron MM, Chen N, Moshaver A, Lee AT, Wellington CL, Hayden MR, Raymond LA. Mutant huntingtin enhances excitotoxic cell death. Molcular and Cellular of Neurosciences 2001 Jan;17(1):41-53.
25. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntingtons disease. Neuron 2002 Mar;33(6):849-60.
26. Li JY, Plomann M, Brundin P. Huntingtons disease: a synaptopathy? Trends in Molecular Medicine 2003 Oct;9(10):414-20.
27. Li L, Murphy TH, Hayden MR, Raymond LA. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. Journal of Neurophysiology 2004 Nov;92(5):2738-46.
28. Cersósimo MG, Micheli FE. Antiglutamatergic drugs in the treatment of Parkinsons disease. In: Handbook of clinical neurology. Koller C, Melamed E, editors. V. 84. Parkinsons disease and related disorders. Part II. New York: Elsevier; 2007: 127-36.
29. Elahi B, Phielipp N, Chen R. N-methyl-D-aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Canadian Journal of Neurological Sciences 2012 Jul;39(4):465-72.
30. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995 Jul;34(7):713-21.
31. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinsons disease. CNS Drugs 2007;21(8):677-92.
32. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinsons disease. Movement Disordres 2010 Jul;25(10):1357-63.
33. Ilzenberg R, Bonuccelli U, Schechtman E, Miniowich A, Strugatsky R, Ceravolo R, Logi C, Rossi C, Klein C, Rabey JM. Association between amantadine and the onset of dementia in Parkinsons disease. Movement Disorders 2006 Sep;21(9):1375-9.
34. Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P. Amantadine treatment as an independent predictor of improved survival in Parkinsons disease. Neurology 1996 Jun;46(6):1551-6.
35. Armstrong MJ, Miyasaki JM; American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012 Aug;79(6):597-603.
36. Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN. Huntingtons disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002 Sep;59(5):694-9.
37. Lucetti C, Del Dotto P, Gambaccini G, Dell Agnello G, Bernardini S, Rossi G, Murri L, Bonuccelli U. IV amantadine improves chorea in Huntingtons disease: an acute randomized, controlled study. Neurology 2003 Jun;60(12):1995-7.
38. OSuilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Archives of Neurology 2003 Jul;60(7):996-8.
39. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntingtons disease. The Cochrane Database of Systematic Reviews 2009;(3):CD006456.
40. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clinical Neuropharmacology 2010 Nov-Dec;33(6):271-5.
41. Fedorova NV,Vetokhina TN. Neuroleptic extrapyramidal disorders. In: Parkinsons disease and movement disorders. Guidelines for physicians. Proceedings of the 2nd National Congress Parkinsons Disease and Movement Disorders (with international participation). Illariushkin SN, Levin OS, editors. Moscow, 2011: 275-80 (In Russian).
42. Botez MI, Botez-Marquard T, Elie R, Le Marec N, Pedraza OL, Lalonde R. Amantadine hydrochloride treatment in olivopontocerebellar atrophy: a long-term follow-up study. European Neurology 1999;41(4):212-5.
  

[ N 2 | | ]